{"product_id":"rocketpharma-pestle-analysis","title":"Rocket Pharma PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our PESTLE analysis of Rocket Pharma—detailing political, economic, social, technological, legal and environmental forces shaping its prospects. Ideal for investors and strategists seeking concise, actionable insights. Purchase the full report to access the complete, downloadable breakdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS FDA and NIH stance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS regulatory priorities directly shape Rocket Pharma trial design, safety monitoring and approval timing. FDA CBER oversees gene therapies with a priority review goal of 6 months and guidance pathways such as RMAT that can accelerate review while imposing long‑term follow‑up recommendations up to 15 years. NIH OBA oversight of recombinant DNA and vectors mandates biosafety and protocol risk management, and stability in leadership\/policy affects trial continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health policy incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolicies like FDA priority review (6-month target) and 7-year orphan exclusivity, alongside public funding, de-risk development and expand access; the global rare disease population is ~300 million and the orphan drug market exceeded $200B in 2024. Wider adoption of newborn screening (US RUSP: 35 core conditions) grows addressable markets. ICH-driven harmonization eases cross-border trial site selection, while 2024–25 public spending pressures could narrow funding windows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply chain risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInternational tensions can disrupt supply of vector manufacturing inputs, plasmids and single-use bioprocess components, increasing CMC timeline volatility for Rocket Pharma. Export controls on biotech materials have hardened, causing batch holds and regulatory delays that affect clinical supply readiness. Diversifying suppliers across regions mitigates interruption risk. Political stability of manufacturing hubs directly impacts reliability of supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic–private partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic–private partnerships provide Rocket Pharma with government grants and consortia that support clinical evidence generation and build specialized infrastructure, lowering effective cost of capital for ultra-rare indications and enabling broader trial networks; alignment with national innovation agendas improves access to facilities and patient registries, while withdrawal of public support can elongate development cycles and increase financing needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrants\/consortia: enable evidence generation and infrastructure\u003c\/li\u003e\n\u003cli\u003eLower cost of capital: critical for ultra-rare programs\u003c\/li\u003e\n\u003cli\u003eNational alignment: better access to registries and sites\u003c\/li\u003e\n\u003cli\u003eRisk: loss of support lengthens timelines, raises financing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reimbursement politics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational debates over high-cost therapies shape payer willingness and budgets: specialty drugs account for roughly 50% of US drug spend, pressuring coverage for Rocket Pharma’s gene therapies, while the Inflation Reduction Act’s drug negotiation (projected ~100 billion USD savings over a decade) increases scrutiny.\u003c\/p\u003e\n\u003cp\u003eOutcomes-based contracts and HTA-driven reference pricing across EU\/UK create cross-country pricing corridors, and election cycles (eg 2024) can flip policy toward tighter cost containment or innovation support.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty drugs ≈50% of US drug spend\u003c\/li\u003e\n\u003cli\u003eIRA drug negotiation ≈100B USD projected savings\/10 yrs\u003c\/li\u003e\n\u003cli\u003eOutcomes-based deals rising in 2023–24\u003c\/li\u003e\n\u003cli\u003eHTA\/reference pricing shape EU\/UK corridors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan exclusivity, FDA priority and IRA pressure reshape rare-disease commercial windows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS regulatory priorities (FDA CBER: 6‑month priority review; RMAT pathways) and 7‑year orphan exclusivity shape Rocket Pharma trial timing and commercial windows. Orphan market \u0026gt;$200B (2024) and ~300M global rare patients expand addressable demand, while IRA drug negotiation (~$100B savings\/10 yrs) and specialty drugs ≈50% of US drug spend increase payer scrutiny. Export controls and geopolitical risks raise CMC\/supply volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA priority review\u003c\/td\u003e\n\u003ctd\u003e6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan market (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease population\u003c\/td\u003e\n\u003ctd\u003e~300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRA projected savings\u003c\/td\u003e\n\u003ctd\u003e~$100B\/10 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug share (US)\u003c\/td\u003e\n\u003ctd\u003e≈50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Rocket Pharma across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—linking trends in gene therapy funding, regulatory scrutiny, reimbursement dynamics, and manufacturing scale-up to strategic risks and opportunities. Each section offers data-backed, forward-looking insights tailored for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Rocket Pharma PESTLE analysis that streamlines external risk assessment and market-position discussions, making it easy to drop into presentations, share across teams, and support rapid strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity and burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGene therapy requires high upfront R\u0026amp;D, GMP manufacturing and multi-year follow-ups, driving Rocket Pharmaceuticals cash burn; Rocket reported cash and equivalents of $231.4 million at March 31, 2025, constraining long-term runway. Market volatility tightens equity windows and raises cost of capital, increasing dilution risk. Milestone-based partnerships can smooth funding but often dilute upside. Efficient, adaptive trial design is critical to preserve runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and payer elasticity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-time gene therapies now carry prices of $2–3.5M (Zolgensma $2.125M, Hemgenix $3.5M) and draw intense budget-impact scrutiny. Payers increasingly seek annuity or outcomes-based contracts to spread cost and enrolment risk. Low prevalence (X-ALD ~1:20,000) constrains volume but can sustain premiums if value proven. Robust HEOR and QALY data (US thresholds ~$100–150k\/QALY) are core commercial assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing scale economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYields, vector productivity and batch success rates drive Rocket Pharma’s COGS; industry reports through 2023–24 show wide variability with effective cost per AAV\/LV dose differing by up to an order of magnitude depending on yield and failure rates.\u003c\/p\u003e\n\u003cp\u003eChoosing internal manufacturing versus CDMO capacity alters fixed-cost absorption, margin and program flexibility—CDMO scale can lower unit cost but reduces control over timing and IP.\u003c\/p\u003e\n\u003cp\u003eProcess intensification (up to ~10x productivity gains reported industry-wide by 2023–24) progressively lowers cost per dose over time.\u003c\/p\u003e\n\u003cp\u003eSupply reliability directly affects launch timing and revenue recognition, with manufacturing delays shifting FDA filings and deferring peak sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX and global launch timing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCurrency swings (EUR\/USD ~1.09 avg 2024; GBP\/USD ~1.28) materially affect reported revenue and input costs across US\/EU\/UK sites, while staggered launches follow regulatory approvals and payer readiness to optimize uptake. Parallel trade and international reference pricing, which studies show can cut prices 10–30%, may compress margins; hedging policies (often covering a high share of forecasted flows) mitigate volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX: EUR\/USD ~1.09 (2024)\u003c\/li\u003e\n\u003cli\u003eGBP\/USD ~1.28 (2024)\u003c\/li\u003e\n\u003cli\u003eIRP impact: −10–30%\u003c\/li\u003e\n\u003cli\u003eStaggered launches tied to regulators\/payers\u003c\/li\u003e\n\u003cli\u003eHedging reduces earnings volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eM\u0026amp;A and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBD deals supply capital, manufacturing capabilities and co-commercialization paths that are critical for Rocket Pharma to advance AAV\/LVV programs; industry partnering activity in 2024 exceeded $200 billion in disclosed deal value, underscoring available capital and collaboration opportunities.\u003c\/p\u003e\n\u003cp\u003eConsolidation among major CDMOs—Thermo Fisher, Catalent and WuXi Biologics—has concentrated vector supply and strengthened pricing power; strategic alliances can accelerate platform expansion into adjacent indications, but integration risk and milestone obligations require active management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBD deals: capital + co-commercialization\u003c\/li\u003e\n\u003cli\u003eCDMO concentration: Thermo Fisher, Catalent, WuXi\u003c\/li\u003e\n\u003cli\u003eStrategic alliances: faster AAV\/LVV indication expansion\u003c\/li\u003e\n\u003cli\u003eRisks: integration, milestone liabilities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan exclusivity, FDA priority and IRA pressure reshape rare-disease commercial windows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh upfront R\u0026amp;D and GMP manufacturing drive cash burn; cash $231.4M (Mar 31, 2025) limits runway and raises dilution risk. Payer scrutiny and outcome\/annuity models pressure pricing despite $2–3.5M gene therapy benchmarks; low prevalence supports premium if HEOR\/QALY strong. CDMO concentration, process gains and FX (EUR\/USD 1.09; GBP\/USD 1.28 in 2024) materially affect COGS and launch timing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$231.4M (3\/31\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice comps\u003c\/td\u003e\n\u003ctd\u003eZolgensma $2.125M; Hemgenix $3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX (2024)\u003c\/td\u003e\n\u003ctd\u003eEUR\/USD 1.09; GBP\/USD 1.28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD activity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200B disclosed (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eRocket Pharma PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe Rocket Pharma PESTLE Analysis preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This is the real, finished file with no placeholders or teasers. The content, layout, and structure match what you’ll download instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162616902009,"sku":"rocketpharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/rocketpharma-pestle-analysis.png?v=1762704653","url":"https:\/\/portersfiveforce.com\/products\/rocketpharma-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}